Alligator Bioscience announced the appointment of Staffan Encrantz and Denise Goode as members of the company's Board of Directors. Mr. Encrantz is the founder and Chairman of Allegro Investment Fund, a $750 million fund which has been investing in companies across a number of industries for 30 years and is also a major shareholder in Alligator Bioscience. Ms. Goode has more than 25 years of experience in business leadership and innovation, having held a number of senior executive and board-level positions in the pharmaceutical and life science industries, including at AstraZeneca.

The new appointees will bring the number of Board members at Alligator Bioscience to eight, including the Chairman. Staffan is a hugely experienced investor having led the growth and development of numerous companies, including start-ups and established businesses, over the last 30 years. Since 2015, he has taken a great interest in Alligator Bioscience, and the company is delighted to have him assume a formal leadership role in the company.

Denise brings with her a huge amount of insight and experience with a deep understanding of the pharmaceutical industry as well as financing, fundraising and business development. Their appointments will further strengthen the leadership of the company and underline commitment to mission of developing antibody-based treatments for cancer while creating outstanding value for shareholders.